Impact of cilostazol on prevention of late failure of autologous vein grafts

Abstract

Objectives

The effectiveness of postoperative medication for the prevention of late graft failure is controversial. We conducted the present study to investigate whether cilostazol improved the mid-term outcomes after infrainguinal autologous vein bypass for chronic limb-threatening ischemia (CLTI).

Methods

From April 1994 to March 2022, we performed 590 de novo infrainguinal bypass procedures using autologous vein grafts (AVGs) in three hospitals. The bypass grafts were classified according to the postoperative prescription of cilostazol. The loss of graft patency and major adverse limb events (MALEs) were set as endpoints. Patients who died within 30 days and grafts that lost primary patency within 30 days after surgery were excluded. Data up to 3 years were analyzed. The cumulative primary patency (PP), assisted primary patency (AP), secondary patency (SP), and freedom from MALE (ffMALE) rates were calculated by the Kaplan–Meier method and compared between the cilostazol group and the non-cilostazol group. After a propensity score matching, same statistical analyses were performed. In addition, a Cox proportional hazards regression analysis that included preoperative factors, intraoperative factors, and postoperative medications was performed to identify whether cilostazol is an independent predictor for the outcomes.

Results

A total of 523 AVGs met inclusion criteria. Kaplan–Meier curves showed that the cilostazol group was superior to the non-cilostazol group in all outcomes, while the cilostazol group was superior to the non-cilostazol group in AP and SP after a propensity score matching. A multivariable analysis showed that non-use of cilostazol was identified as an independent predictor for loss of AP, SP, and ffMALE.

Conclusions

Cilostazol improved the mid-term outcomes after infrainguinal autologous vein bypass.

Keywords

Cilostazol autologous vein graft graft patency major adverse limb event

Get full access to this article

View all access options for this article.

References

Conte

Bradbury

Kolh

, et al. Global vascular guidelines on the management of chronic limb-threatening Ischemia. Eur J Vasc Endovasc Surg 2019; 58: S1–S109.

Bedenis

Lethaby

Maxwell

, et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2015; 2015: CD000535.

Vrsalovic

Aboyans

. Antithrombotic therapy in lower extremity artery disease. Curr Vasc Pharmacol 2020; 18: 215–222.

Hess

Norgren

Ansel

, et al. A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. Circulation 2017; 135: 2534–2555.

Soga

Iida

Kawasaki

, et al. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. Eur J Vasc Endovasc Surg 2012; 44: 577–581.

Iida

Yokoi

Soga

, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study. Circulation 2013; 127: 2307–2315.

Nanto

Iida

Takahara

, et al. Effect of cilostazol following endovascular intervention for peripheral artery disease. Angiology 2015; 66: 774–778.

Warner

Greaves

Larson

, et al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg 2014; 59: 1607–1614.

Mii

Tanaka

Kyuragi

, et al. Raison d’etre of tibial artery bypass for intermittent claudication in the era of endovascular therapy. Circ J 2016; 80: 1460–1469.

10.

Rutherford

Baker

Ernst

, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517–538.

11.

Conte

Geraghty

Bradbury

, et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg 2009; 50: 1462–1473.

12.

Belch

Dormandy

Biasi

, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825–833.

13.

Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomized trial. Lancet 2000; 355: 346-351.

14.

Owens

Conte

. Lower extremity vein graft failure: a translational approach. Vasc Med 2008; 13: 63–74.

15.

Gasper

Owens

Kim

, et al. Thirty-day vein remodeling is predictive of midterm graft patency after lower extremity bypass. J Vasc Surg 2013; 57: 9–18.

16.

DeSart

Kubilis

, et al. Heterogeneous and dynamic lumen remodeling of the entire infrainguinal vein bypass grafts in patients. J Vasc Surg 2020; 71: 1620–1628.

17.

Kudo

Kondo

Muto

, et al. Cilostazol suppresses neointimal hyperplasia in canine vein grafts. Surg Today 2009; 39: 128–132.

18.

Giannoukas

Paraskevas

Koutsias

, et al. The role of oral vitamin K antagonists in the outcome of infrainguinal bypass procedures. Angiology 2014; 65: 568–573.

19.

Jackson

Johnson

Williford

, et al. The effect of anticoagulation therapy and graft selection on the ischemic consequences of femoropopliteal bypass graft occlusion: results from a multicenter randomized clinical trial. J Vasc Surg 2002; 35: 292–298.

20.

Yamaguchi

. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000; 31: 817–821.

21.

Govsyeyev

Nehler

Conte

, et al. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. J Vasc Surg 2023; 77: 1107–1118, DOI: 10.1016/j.jvs.2022.11.062.

22.

Alpagut

Ugurlucan

Banach

, et al.

Does gender influence the patency of infrainguinal bypass graft?

Angiology 2008; 59: 278–282.

23.

Duffy

Adams

Callas

, et al. The influence of gender on functional outcomes of lower extremity bypass. J Vasc Surg 2014; 60: 1282–1290.

24.

Wang

Shu

, et al. The effect of gender on outcomes after lower extremity revascularization. J Vasc Surg 2017; 65: 889–906.